News
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.
Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback